News >

Rethinking Treatment Schemas in Relapsed/Refractory Multiple Myeloma

Caroline Seymour
Published: Wednesday, Jul 10, 2019

Mounzer E. Agha, MD

Mounzer E. Agha, MD

Due to the chronicity of the disease, patients with multiple myeloma are likely to relapse or become refractory to available treatments. However, monoclonal antibodies, immunomodulatory (IMiD) drugs, and novel compounds have shown impressive efficacy in restoring response rates and possible remissions.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication